Glycoprotein hormone that stimulates red blood cell production (erythropoiesis). FDA-approved for anemia treatment. Known for endurance performance effects.
Last Updated: May 2026
EPO (Erythropoietin) is a 165-amino-acid glycoprotein hormone produced primarily by the kidneys, central to red blood cell production (erythropoiesis). Recombinant EPO (epoetin alfa, darbepoetin alfa, and other variants) is FDA-approved for treatment of anemia in chronic kidney disease, chemotherapy-induced anemia, and certain other anemic conditions. EPO is also widely known for performance-enhancement misuse in endurance sports and is prohibited by WADA. Research-grade EPO is sold by third-party laboratories for laboratory use.
EPO (Erythropoietin) is a glycoprotein hormone produced primarily by peritubular capillary endothelial cells in the kidney cortex, responding to tissue hypoxia by stimulating bone marrow erythroid progenitor cells to produce mature red blood cells. Recombinant EPO replicates this natural signaling pathway. Beyond erythropoiesis, EPO has tissue-protective effects through alternative receptor heterodimers — the mechanism that ARA-290 was engineered to capture selectively. Evidence level: FDA-approved (chronic kidney disease anemia, chemotherapy anemia); extensive clinical and post-market data.
Recombinant EPO products (epoetin alfa as Epogen/Procrit, darbepoetin alfa as Aranesp) are FDA-approved for chronic kidney disease anemia, chemotherapy-induced anemia, and certain other anemic conditions, with extensive Phase 3 and post-market evidence supporting these indications. The clinical evidence base is among the largest for any therapeutic peptide. Cardiovascular safety considerations led to revised dosing guidelines targeting lower hematocrit endpoints than originally pursued. Evidence level: FDA-approved, multiple indications; extensive Phase 3 and post-market data.
EPO has dual effects (erythropoiesis + tissue protection); ARA-290 was engineered to capture EPO's tissue-protective effects without erythropoiesis to sidestep the cardiovascular risks of hematocrit elevation.
| Compound | Erythropoiesis | Tissue protection | FDA status |
|---|---|---|---|
| EPO (recombinant) | Yes | Yes | FDA-approved (anemia) |
| ARA-290 | No | Yes (selective) | Phase 2 |
| Natural EPO | Yes | Yes | Endogenous hormone |
EPO administration produces dose-related cardiovascular risks — hypertension, thrombosis, cardiovascular events — particularly when hematocrit is raised above physiological levels. These risks led to FDA black-box warnings and revised clinical dosing guidance targeting lower hematocrit endpoints. Other side effects include injection-site reactions, fever, and in rare cases pure red cell aplasia from anti-EPO antibodies. Evidence level: Extensive post-market safety data; FDA prescribing information detailed.
Recombinant EPO products are FDA-approved for chronic kidney disease anemia, chemotherapy-induced anemia, and related indications, with EMA and other major regulator approvals worldwide. EPO is on the WADA Prohibited List (Section S2 — Peptide Hormones) and is prohibited in competitive sport. Research-grade EPO is sold by third-party laboratories for laboratory use. Regulatory context in FDA peptide regulation 2025–2026 timeline.
Because FDA-approved EPO products (Epogen, Procrit, Aranesp) are prescription-only pharmacy distributed, distinct from research-grade EPO sold by third-party laboratories — those are different supply chains with different quality controls. Research-grade EPO is subject to wider purity variance, glycosylation pattern variation (which affects bioactivity), and inconsistent endotoxin control. Independent third-party HPLC testing and mass spectrometry are the standard quality signals; for a glycoprotein hormone, glycosylation analysis would also be relevant for pharmaceutical-grade equivalence — but that level of testing is not standard in research-grade markets. Guidance in how-to-test-peptides hub.
Peptigrity purchases EPO vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC, mass spectrometry, and endotoxin analysis, and publishes the unedited certificate of analysis. The glycoprotein nature limits the discriminating power of standard peptide tests. Methodology in how we calculate trust scores.
FDA-approved EPO products (epoetin alfa, darbepoetin alfa) treat anemia in chronic kidney disease, chemotherapy-induced anemia, and certain other anemic conditions. Use is by prescription through licensed pharmacies under physician supervision with hematocrit monitoring.
FDA-approved EPO products are available by prescription. Research-grade EPO is legal to purchase as a research chemical for laboratory use in most jurisdictions, but is not approved for human consumption. EPO is prohibited by WADA in competitive sport. Country breakdown in peptide legal status guide.
Yes. EPO is on the WADA Prohibited List (Section S2 — Peptide Hormones) and competitive athletes face sanctions for use. Detection methods include direct urinary EPO analysis and the Athlete Biological Passport. For drug-testing context, see do peptides show up on drug tests.
EPO raises hematocrit (red blood cell concentration), which increases blood viscosity and cardiovascular risk — particularly during dehydration or sleep. EPO misuse has been associated with sudden cardiac death in endurance athletes. The cardiovascular risks led to FDA dosing revisions even for medical use, and unmonitored performance-enhancement use carries substantially higher risk.
Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation and endotoxin testing. Note that for a glycoprotein hormone, standard peptide testing has less discriminating power than for non-glycosylated peptides; glycosylation analysis would be relevant for pharmaceutical-grade equivalence but is not standard in research-grade markets. COA interpretation in red flags in peptide certificates of analysis.
No. Medical EPO use requires physician supervision with hematocrit monitoring; performance-enhancement use is prohibited by WADA and carries serious cardiovascular risk. Peptigrity is an independent review platform, not a medical authority. Anyone considering EPO use should consult a licensed physician.
This section is for educational and informational purposes only and does not constitute medical advice. FDA-approved EPO products (Epogen, Procrit, Aranesp) require a prescription; research-grade EPO sold for laboratory use is not the FDA-approved prescription product. EPO is prohibited by WADA in competitive sport. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.